Regeneron can’t dodge Allele’s COVID patent suit
07-03-2022
Regeneron convinces PTAB to review Novartis syringe patent
28-10-2021
Novartis withdraws bid to block US Regeneron imports
04-05-2021
Lev Radin / Shutterstock.com
Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Novartis, Regeneron, Vetter Pharma International, patent infringement, antitrust, USPTO, syringes
